Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer.

Our transformative product candidates - best in class - Adoptive Cell Therapies and Bispecific TCR molecules. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT® technology.

Our mission is to deliver the power of T-cell redirecting immunotherapies to cancer patients. In order to fully exploit the potential of Immatics' product pipeline and technologies we invite others to join us on this exciting mission.

Our Partners


Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies, Jan 09, 2017.

Learn more


Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies, Aug 26, 2015.

Learn more


MorphoSys and Immatics Biotechnologies Enter Strategic Alliance in Immuno-oncology, Aug 25, 2015.

Learn more


Immatics and Roche sign cancer vaccine and immunotherapy collaboration, Nov 13, 2013.

Learn more

Contact Us about Partnering Opportunities


Immatics Biotechnologies GmbH
Business Development Group

Machtlfinger Str. 11
81379 München

Meet our Team at


News, USA

Immatics at the BIO International Convention 2018 (June 4-7) in Boston, MA […]

Read more



Immatics Events Q2 2018

Read more